Tag: Atai Life Sciences - Page 7 - Psychedelic Alpha

Read more about the article IntelGenx Expands Psychedelics Collaboration with atai Life Sciences with Signing of Second Feasibility Agreement

IntelGenx Expands Psychedelics Collaboration with atai Life Sciences with Signing of Second Feasibility Agreement

Post published:May 12, 2021
Post category:Press Release

Read more about the article IntelGenx Announces Shareholder Approval of atai Investment

IntelGenx Announces Shareholder Approval of atai Investment

Post published:May 11, 2021
Post category:Press Release

Read more about the article atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders

atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders

Post published:April 7, 2021
Post category:Press Release

Read more about the article atai Life Sciences AG Announces Equity Investment in and Strategic Partnership with IntelGenx Technologies Corp.

atai Life Sciences AG Announces Equity Investment in and Strategic Partnership with IntelGenx Technologies Corp.

Post published:March 17, 2021
Post category:Press Release

Read more about the article Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders

Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders

Post published:March 16, 2021
Post category:Press Release

Read more about the article IntelGenx Announces Strategic Partnership with atai Life Sciences and Proposed TSX Graduation

IntelGenx Announces Strategic Partnership with atai Life Sciences and Proposed TSX Graduation

Post published:March 15, 2021
Post category:Press Release

Read more about the article atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round

atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round

Post published:March 3, 2021
Post category:Press Release

Read more about the article atai Life Sciences to Collaborate with Massachusetts General Hospital to Accelerate Discovery of Mechanisms Underlying Therapeutic Effects of Psychedelic Agents

atai Life Sciences to Collaborate with Massachusetts General Hospital to Accelerate Discovery of Mechanisms Underlying Therapeutic Effects of Psychedelic Agents

Post published:January 26, 2021
Post category:Press Release

Read more about the article atai Life Sciences Appoints New Chief Financial Officer and Chief Medical Officer

atai Life Sciences Appoints New Chief Financial Officer and Chief Medical Officer

Post published:December 16, 2020
Post category:Press Release

Read more about the article ATAI Life Sciences Announces Closing of $125 Million Series C Financing Round

ATAI Life Sciences Announces Closing of $125 Million Series C Financing Round

Post published:November 23, 2020
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.